The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Re-exposure to blinatumomab after CD19-positive relapse: Experience from three trials in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (R/R ALL).
 
Max S. Topp
Honoraria - Amgen
Consulting or Advisory Role - Amgen
Travel, Accommodations, Expenses - Amgen; Roche Pharma AG; Takeda
 
Matthias Stelljes
No Relationships to Disclose
 
Gerhard Zugmaier
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Phillip Barnette
No Relationships to Disclose
 
Leonard T. Heffner
No Relationships to Disclose
 
Tanya M. Trippett
No Relationships to Disclose
 
Ralf C. Bargou
Honoraria - Amgen; Novartis; Pfizer
Consulting or Advisory Role - Amgen; Novartis; Pfizer
Patents, Royalties, Other Intellectual Property - Amgen
 
Chris Holland
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Jonathan Benjamin
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Mark Robert Litzow
Honoraria - Amgen
Consulting or Advisory Role - Amgen; MEI Pharma; Sigma-Tau
Research Funding - Amgen; Astellas Pharma